176 related articles for article (PubMed ID: 18338758)
1. Changes in causes of death over time after treatment for invasive aspergillosis.
Wingard JR; Ribaud P; Schlamm HT; Herbrecht R
Cancer; 2008 May; 112(10):2309-12. PubMed ID: 18338758
[TBL] [Abstract][Full Text] [Related]
2. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
4. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
5. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
7. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.
Steinbach WJ; Benjamin DK; Kontoyiannis DP; Perfect JR; Lutsar I; Marr KA; Lionakis MS; Torres HA; Jafri H; Walsh TJ
Clin Infect Dis; 2004 Jul; 39(2):192-8. PubMed ID: 15307028
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
12. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole].
Mattner F; Chaberny IF; Weissbrodt H; Fischer S; Gastmeier P; Haubitz B; Gottlieb J; Mattner L; Strueber M
Mycoses; 2005; 48 Suppl 1():51-5. PubMed ID: 15826288
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers.
Cordonnier C; Ribaud P; Herbrecht R; Milpied N; Valteau-Couanet D; Morgan C; Wade A;
Clin Infect Dis; 2006 Apr; 42(7):955-63. PubMed ID: 16511759
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole versus amphotericin B for invasive aspergillosis.
Blot F; Edé C; Nitenberg GM
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695
[No Abstract] [Full Text] [Related]
16. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B.
Linden PK; Coley K; Fontes P; Fung JJ; Kusne S
Clin Infect Dis; 2003 Jul; 37(1):17-25. PubMed ID: 12830404
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole versus amphotericin B for invasive aspergillosis.
Karthaus M
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12494937
[No Abstract] [Full Text] [Related]
18. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
Luong ML; Husain S; Rotstein C
Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
[TBL] [Abstract][Full Text] [Related]
19. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
[TBL] [Abstract][Full Text] [Related]
20. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.
Klein KC; Blackwood RA
Pediatrics; 2006 Aug; 118(2):e506-8. PubMed ID: 16816005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
